JPMorgan reiterates Ionis stock rating on dosing advantage outlook

JPMorgan has reaffirmed an Overweight rating and set a $76.00 price target for Ionis Pharmaceuticals (NASDAQ: IONS). Currently trading at $61.05 with a market cap of $10.15 billion, Ionis delivered a 43% return over the past year. The firm highlighted the efficacy of Tryngolza and competitor plozasiran as almost identical in severe hypertriglyceridemia based on phase III data for plozasiran.

Plozasiran's main advantage lies in dosing convenience, with quarterly administration compared to monthly for Tryngolza. JPMorgan sees a slight edge for plozasiran in liver enzymes, platelets, and liver fat, though these factors are not considered significant to Tryngolza's profile. The firm is monitoring ION775, Ionis's siRNA in phase II trials, which could offer semi-annual or annual dosing approximately 18 months from a phase III start.

This product could surpass plozasiran on dosing frequency and build on Tryngolza's foundation in severe hypertriglyceridemia. Ionis's prospects are viewed favorably due to low market expectations for pelacarsen and a favorable launch story following the update. Analysts do not anticipate profitability this year, according to an InvestingPro tip.

For further insights, investors can access the Pro Research Report on IONS, available for this and 1,400+ other US equities. Ionis reported a narrower-than-expected loss in Q2, alongside strong revenue, supported by increased sales of new medications and ongoing collaboration income. H.C. Wainwright adjusted its price target for Ionis to $115 from $125, maintaining a Buy rating, while Canaccord Genuity also reaffirmed a Buy rating with a $95 price target.

BMO Capital initiated coverage with a Market Perform rating and a $60 price target, noting the company's shift to self-marketed product launches. These developments highlight Ionis's evolving business model and the market's varied expectations.